 |
 |
Jun 17, 2013
Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
Jun 06, 2013
Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
May 31, 2013
Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
 |
 |